UNSPSC 51291907: Oxitriptan

This classification denotes an amino acid derivative with the molecular formula C11H12N2O3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier C1LJO185Q9, chemically known as tryptophan, 5-hydroxy-, l- but more generally known as oxitriptan, which bears U.S. NIH Compound Identifier 144. European Medicines Agency schedules Oxitriptan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09541MIG.

UNSPSC 51291907 Oxitriptan is a Commodity code that in practice captures state and local procurement of pharmaceutical products and related health-system supplies, though the recent opportunities posted under this code show limited direct alignment with oxitriptan specifically. State and local governments buying under this code are acquiring naloxone (opioid antagonist), safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through both individual agency procurement and cooperative purchasing vehicles. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances serving state departments, local government facilities, and participating jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP).

Recent activity spans Florida, Texas, Minnesota, and Oregon. Three representative solicitations characterize the current market: Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline and quarterly deliveries required; the Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, requesting vendor information on direct-to-manufacturer prescription fulfillment capabilities and contracting models to support a Therapeutic Pharmacy Initiative; and MMCAP (Minnesota Department of Administration) issued RFP S1070000015802 on January 20, 2026, with a March 26, 2026 due date to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, requiring vendor compliance with cGMP, DSCSA, FDA requirements, and authorization through three specified wholesalers with performance penalties of $200 to $1,500 per violation.